Issues
-
Cover Image
Cover Image
Composite histological image of a LS174T xenograft combining information from hematoxylin and eosin, CA9, and CD31 stains depicts the complexity of the tumor, showing blood lakes (red), small necrotic regions (blue), widespread hypoxic regions (yellow), and red blood cells (white). The composition of the tumor matches the perfusion and oxygen saturation patterns seen in dynamic contrast–enhanced ultrasound (DCEUS) and photoacoustic (PA) imaging scans, respectively. When used in combination, DCEUS and PA imaging have the potential to facilitate the discrimination between blood lakes and necrotic areas. For details, see article by Bar-Zion and colleagues on page 4320. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Cancer Research 75th Anniversary Commentaries
Review
Meeting Report
Integrated Systems and Technologies
Microenvironment and Immunology
Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency
Incipient Melanoma Brain Metastases Instigate Astrogliosis and Neuroinflammation
Molecular and Cellular Pathobiology
Nucleolin Promotes Heat Shock–Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis
HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells
Therapeutics, Targets, and Chemical Biology
Eradication of Acute Myeloid Leukemia with FLT3 Ligand–Targeted miR-150 Nanoparticles
Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth
Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy
Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
Tumor and Stem Cell Biology
DNMT1 Inhibition Reprograms Pancreatic Cancer Stem Cells via Upregulation of the miR-17-92 Cluster
Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.